ArsenalBio | BiotechTV

top of page

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same...

Company News

10 hours ago

Next generation T-cell engineering with ArsenalBio

Co-founder, Chairman & CEO Ken Drazan explains the array of applications that Arsenal engineers into its CAR-T cells.

Tech + Tours

Nov 20, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

Next generation T-cell engineering with ArsenalBio

Follow BiotechTV

Sponsors

Sponsor Spotlight